avapritinib expect nda pdgfr gist also includ kit gist
manag plan disclos initi gist data pivot trial follow
pivot trial avapritinib sm remain on-track begin continu
believ avapritinib sale potenti well reiter outperform rate
blueprint studi avapritinib inhibitor kit exon kit
pdgfr mutat patient gastrointestin stromal tumor gist
blueprint anticip present updat data phase navig studi
like includ patient pdgfr-driven diseas
line kit-driven diseas initi data patient line diseas data
form basi anticip nda submiss slate treatment
patient pdgfr-driven diseas drug hold breakthrough therapi
design line kit-driven diseas plan includ patient
line diseas new inform manag indic expand potenti
near-term market avapritinib patient
data updat also guid path forward patient line diseas
blueprint anticip start pivot phase ii line gist studi
trial random either all-com specif genet driver diseas
receiv avapritinib sutent assum similar mutat cohort expect
investor use orr second line benchmark
competit line set meanwhil phase studi voyag
avapritinib vs regorafenib patient line diseas continu enrol model
peak sale avapritinib gist
avapritinib also develop use system mastocytosi sm sm diseas
character accumul mast cell divers organ lead rang
symptom caus degranul mast cell within affect organ sm
rapidli progress advanc slowli progress indol smolder sm
regardless rate diseas progress vast major patient possess kit
mutat avapritinib shown clinic activ blueprint plan
present updat phase data advanc sm later like
avapritinib potenti registr phase ii pathfind trial advanc sm
expect begin quarter phase blueprint observ efficaci dose low
believ maxim efficaci obtain dose least therefor
pathfind enrol patient treat avapritinib dose
primari endpoint trial iwg respons
pleas see page report import disclosur
blueprint aim improv upon alreadi highli success drug develop strategi
select inhibit kinas activ cancer diseas compani
creat uniqu kinase-specif chemic librari enabl gener
potenti potent specif small molecul inhibitor compani uniqu
chemistri combin biolog insight obtain genom analys
produc lead candid avapritinib advanc
clinic studi demonstr robust proof-of-concept think drug could
combin commerci potenti compani expect file nda
avapritinib pdgfr-driven line kit-driven gist blueprint also
establish partnership roch immuno-oncolog target expect share
appreci pipelin candid advanc
initi patient screen phase ii studi
avapritinib advanc sm
present updat data avapritinib
gist sm
initi pivot phase ii studi
avapritinib indol sm
avapritinib success develop
treatment sm gist
success develop avapritinib
addit indic
success develop
success develop pipelin
treatment
avapritinib sale
advantag partnership
clinic setback delay discontinu
develop avapritinib
lower penetr weaker price
power reduc sale estim
ww commerci opportun sm gist
early-stag oncolog compani focus develop
select potent kinas inhibitor patient genet defin cancer
boast proprietari librari compound explor novel uniqu chemic
space thu bear littl resembl use tradit pharmaceut
industri blueprint also develop biolog capabl enabl discov new
diseas target cancer rare genet disord inflammatori diseas compani
drug discoveri platform produc lead candid avapritinib phase i/ii
clinic develop sm gist ret-inhibitor
compani initi ind-en studi inhibitor fop
addit io target address partnership roch
potenti pivot random phase ii pioneer trial indolent/smold sm
also begin trial enrol patient two part receiv placebo
avapritinib primari endpoint pioneer blueprint design patient report
outcom assay data support design present
like first part pioneer two dose avapritinib test
valid one dose select advanc part pioneer
importantli blueprint expect avapritinib dose pioneer
pathfind dose expect provid superior chronic toler patient
significantli manag report benefit low dose avapritinib observ
phase advanc sm trial align symptom identifi import
indolent/smold sm patient design
manag also note sm registri find patient routin
misdiagnos typic sm patient misdiagnos time prior receiv
correct sm diagnosi fact review harvard heme/onc databas identifi
mani patient mutat diagnos
sm manag report undiagnos patient
subsequ confirm sm therefor sm market may significantli
larger exist preval estim indic use exist preval estim
model includ peak sale sm across advanc smolder indol form
enrol continu dose-expans portion phase arrow studi
ret-fus inhibitor select daili dose patient
enrol one four cohort ret-alt nsclc previous treat tki
ret-alt nsclc previous treat tki mtc patient patient
ret-alt solid tumor blueprint expect present updat data studi
end begin recal initi data demonstr respons
rate rang patient broad rang mutat eager
see matur data set hope higher respons rate patient dose
longer period time chosen therapeut dose
june blueprint enter collabor
cstone obtain exclus right develop commerci avapritinib
china hong kong macau taiwan compani anticip initi
chines proof-of-concept studi examin combin
antibodi use front line blueprint indic collabor also allow
greater access patient acceler develop patient
subset includ tki-nav patient approxim half patient diagnos
year expect asian territori cover agreement
enrol on-going phase studi expand mainland china
blueprint cstone track submit ind china allow
initi studi outlin
blueprint continu advanc inhibitor preclin candid
treatment fibrodysplasia ossifican progressiva fop compani present pre-
clinic data compound asbmr septemb track file ind
blueprint report net loss versu quarterli revenu
aid up-front payment due collabor cstone
compani cash balanc expect support oper
develop kinas inhibitor patient genet defin
cancer compani novel chemic librari combin biolog insight
engend divers pipelin oncolog candid avapritinib avapritinib
inhibitor kit exon mutat known play role system
mastocytosi sm resist form gastrointestin stromal tumor gist
think drug could commerci potenti across two tumor type
phase studi sm gist deliv promis data drug receiv
breakthrough therapi design treatment pdgfr-driven gist blueprint
anticip file approv pdgfr-driven gist line kit-driven gist
patient base data expans cohort pivot phase studi
patient line gist began june compani present updat data
avapritinib sm eha anticip initi registration-en
pathfind studi advanc sm registrationally-direct phase ii
studi pioneer patient indol sm start late ret
inhibitor design overcom resist ret-inhibitor produc
compel proof-ofconcept data orr phase trial dose expans cohort
on-going select inhibitor pathway activ
subset hepatocellular carcinoma patient updat data
present esmo addit cohort tki-nav patient
ad studi inform requir determin best
possibl set advanc could support world-wide
sale addit pipelin candid includ inhibitor
fibrodysplasia ossifican progressiva fop preclin develop blueprint
roch collabor discov develop kinas inhibitor applic
present preclin data fop
initi screen registration-en phase ii studi pathfind avapritinib advanc sm
data pivot phase expans cohort avapritinib pdgfr-driven gist
present addit data phase expans cohort avapritinib kit-driven gist
present updat phase data avapritinib advanc sm explor
initi registr enabl phase ii studi pioneer avapritinib indol smolder sm
submit ind chines health author
submit ind fop
present updat data phase arrow studi ret-driven tumor
submit nda avapritinib pdgfr-driven gist line kit-driven gist
cowen compani
cowen compani
cowen compani
revenu revenu revenu grant incom prefer stock dividendspre-tax rate incom incom revenu sm revenu revenu grant incom rate incom incom cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
unprofit approv product like need
rais addit capit public market prior turn profit blueprint lead
candid face number clinic regulatori commerci
hurdl prior becom success make invest recommend earli stage
pre-commerci biotechnolog compani base upon assess technolog
probabl pipelin success potenti market opportun event
success howev compani lack tradit financi metric
believ good methodolog assign specif target price
